Abstract
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure in clinical practice. 99mTc-pyrophosphate scintigraphy (PYP-scan) improves the accuracy of ATTR-CM detection, enabling timely initiation of tafamidis, a drug that slows the progression of ATTR-CM and lowers the risk of adverse cardiac events. We assessed the cost-effectiveness of universal systematic screening (USS) using PYP-scans in patients aged 60 years or older with heart failure with preserved ejection fraction (HFpEF) and ventricular wall thickness of at least 12mm.
Methods Two screening strategies, USS of ATTR-CM with PYP-scan versus selected clinical referrals for PYP-scan in standard-of-care (SoC), were compared in a model-based assessment. Treatment decisions were based upon the accuracy of each screening strategy, which was followed by Markov state transitions across NYHA functional classes and death. Model inputs were identified from a literature review. We calculated lifetime cost in 2022 US dollars and quality adjusted life-years (QALYs) of each strategy. The primary outcome was the incremental cost-effectiveness ratio (ICER).
Results The USS was associated with a significant increase in lifetime costs ($124,380 vs. $70,412) and modest improvement in QALYs (4.42 QALYs vs 4.36 QALYs). The ICER for the USS was $919,509 per QALY gained. ICER was sensitive to the age at the time of ATTR-CM diagnosis, true prevalence rate of ATTR-CM, and daily cost of tafamidis.
Conclusions Owing to the high cost of treatment with tafamidis, USS along with PYP scan for ATTR-CM in older HFpEF patients with ventricular wall thickening is unlikely to become a cost-effective strategy at a liberal WTP threshold.
What is Known
- ATTR-CM is a rare but serious condition that leads to a restrictive cardiomyopathy with symptoms that mimic heart failure from other causes (e.g., HFpEF).
- PYP-scan, when it is used along with the other conventional diagnostic tests, is a non-invasive diagnostic tool that sensitively and specifically detect ATTR-CM followed by a timely treatment with tafamidis.
- Tafamidis can slow down ATTR-CM progression and improve survival.
What the Study Adds
- This is the first attempt to evaluate the cost-effectiveness of universal systematic screening of ATTR-CM using PYP-scans in older HFpEF patients with ventricular wall thickening.
- The study found that the universal systematic screening is not cost-effective compared to standard-of-care at a liberal WTP threshold, mainly due to the costly treatment option.
- The study identified the key parameters that affect the cost-effectiveness of screening, such as age, prevalence, and drug cost.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding to support this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This model-based cost-effectiveness study does not meet the human subject research criteria.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Funding There was no funding for this research.
Declaration of Interests Anson Lau serves as a Senior Medical Advisor in AstraZeneca. Kibum Kim has received research funding from Renalytix AI, Grail LLC (a subsidiary of Illumina Inc.), and AstraZeneca. Robert DiDomenico has received research funding from the Chicago Department of Public Health, Cook County Department of Public Health, Otho S.A. Sprague Memorial Institute, and CSL Behring and has served on advisory boards for Abiomed and PhaseBio Pharmaceuticals.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos